Cannabis for refractory epilepsy in children : a review focusing on CDKL5 Deficiency Disorder Tristan Dale, Jenny Downs, Heather Olson, Ann Marie Bergin, Stephanie Smith and Helen Leonard Epilepsy Research, 2019 DOI: https://doi.org/doi:10.1016/j.eplepsyres.2019.02.001 Abstract Severe paediatric epilepsies such as CDKL5 Deficiency Disorder (CDD) are extremely debilitating, largely due to the early-onset and refractory nature of the seizures. Existing treatment options are often ineffective and associated with a host of adverse effects, causing those that are affected to seek alternative treatments. Cannabis based products have attracted significant attention over recent years, primarily driven by reports of miraculous cures and a renewed public preference for ‘natural’ therapies, [...]
Lire la suiteExtractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses Melissa M. Lewis-Bakker, Yi Yang, Rupali Vyawahare, and Lakshmi P. Kotra Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0067 Abstract Introduction : Phytocannabinoids, characteristic compounds produced by medical cannabis, interact with cannabinoid (CB) receptors (CB1 and CB2) as well as other receptor systems to exhibit their corresponding pharmacological effects. In their natural form, CBs such as D9-tetrahydrocannabinolic acid and cannabidiolic acid are inactive at these receptors, while their decarboxylated forms (D9 tetrahydrocannabinol and cannabidiol, respectively) are potent ligands at CB receptors. Thus, extraction and processing [...]
Lire la suiteCannabis Chemovar Nomenclature Misrepresents Chemical and Genetic Diversity; Survey of Variations in Chemical Profiles and Genetic Markers in Nevada Medical Cannabis Samples Ulrich Reimann-Philipp, Mark Speck, Cindy Orser, Steve Johnson, Aaron Hilyard, Helen Turner, Alexander J. Stokes, and Andrea L. Small-Howard Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0063 Abstract Introduction : Medical cannabis patients receive clinical benefits from the secondary metabolites of the plant, which contain a variety of cannabinoids and terpenoids in combinations that can be used to classify the chemovars. State-regulated medical cannabis programs rely on breeder-reported ‘‘strain’’ names both within diversion control systems and to [...]
Lire la suitePotency Analysis of Medical Marijuana Products from New York State Lingyun Li, Bryan C. Duffy, Lorie A. Durocher, Mark A. Dittmar, Robert A. Acosta, Emily R. Delaney, Lei Li, Kenneth M. Aldous and David C. Spink Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0037 Abstract Introduction : In the United States, medicalmarijuana programs have been established in 29 states and the District of Columbia. In 2014, New York State (NYS) approved medical marijuana legislation, and its program became fully operational in January of 2016. Products manufactured under the auspices of the program may be used by certified patients in [...]
Lire la suiteLe Cannabidiol, l’autre canabinoïde présent dans le cannabis : une piste thérapeutique prometteuse? Traiter la dépendance avec du cannabidiol ? Si peu d’études ont pour l’heure été menées chez l’Homme, l’idée fait son chemin... et inspire les instigateurs d’une étude-pilote «CANNAVAP». Grégoire Cleirec et Pierre Poloméni Publié le 20 Mai 2019 par : Revue SWAPS n°90, "Du Cannabis Thérapeutique à la Régulation". http://vih.org/20190520/cannabidiol-lautre-canabinoide-present-cannabis-piste-therapeutique-prometteuse/141891 L’Agence nationale de sécurité du médicament (ANSM) a annoncé récemment la création d’un comité scientifique spécialisé sur «l’évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis thérapeutique en France». Une façon de combler notre retard. À [...]
Lire la suiteRevue SWAPS n°90: Du Cannabis Thérapeutique à la Régulation, 1er trimestre 2019 EDITO S’agissant de la disponibilité du cannabis thérapeutique en France, la ministre de la santé, Agnès Buzyn, avait quelque peu entrouvert la porte : «C’est peut-être un retard que la France a pris quant à la recherche et au développement du cannabis médical. D’autres pays l’ont fait. (…) il n’y a aucune raison d’exclure, sous prétexte que c’est du cannabis, une molécule qui peut être intéressante pour le traitement de certaines douleurs très invalidantes». De fait, l’Agence nationale de sécurité du médicament (ANSM) a annoncé récemment (lire page 21) la [...]
Lire la suiteA role for cannabidiol in psychiatry? Keep calm and follow the drug development rules Gabriella Gobbi THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2019, VOL. 20, NO. 2, 98–100 Commentary https://doi.org/10.1080/15622975.2019.1584680 Along with tetrahydrocannabinol (THC), cannabidiol (CBD) is one of the main pharmacological components of Cannabis sativa and indica. Unlike THC, which binds CB1 receptors, CBD does not cause any dependence, and acts mostly via 5-HT1A and TPRV1 receptors (De Gregorio et al. 2018). Khoury et al. (2019) recently published a systematic review on the role of cannabidiol in psychiatry in the World Journal of Biological Psychiatry. After analysing 609 articles, they found six case reports, [...]
Lire la suiteEffects of Cannabidiol and a Novel Cannabidiol Analog against Tactile Allodynia in a Murine Model of Cisplatin-Induced Neuropathy: Enhanced Effects of Sub-Analgesic Doses of Morphine Hannah Marie Harris, Waseem Gul, Mahmoud A. ElSohly, Kenneth J. Sufka Medical Cannabis and Cannabinoids, 2018, 1, 54–59 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489077 Abstract Objective : This research examined whether a cannabidiol (CBD)-opioid pharmacotherapy could attenuate cisplatin-induced tactile allodynia. Methods : Mice (C57BL/6) were given 6 doses of 2.3 mg/kg cisplatin intraperitoneally (IP) on alternating days to induce tactile allodynia as quantified using an electric von Frey (eVF). Test groups in Experiment 1 received either vehicle, 0.1 [...]
Lire la suitePharmacokinetics and Tolerability of Δ9-THC-Hemisuccinate in a Suppository Formulation as an Alternative to Capsules for the Systemic Delivery of Δ9-THC Mahmoud A. ElSohly, Waseem Gul, Larry A. Walker Medical Cannabis and Cannabinoids, 2018, 1, 44–53 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489037 Abstract The objectives of this study were: (1) to assess the safety, tolerability, and pharmacokinetics of ascending doses of Δ9- tetrahydrocannabinol-hemisuccinate (THC-HS) after rectal administration as suppositories in male volunteers; and (2) to compare the pharmacokinetics of oral administration of Δ9-tetrahydrocannabinol (Δ9-THC) with an equivalent amount of Δ9-THC delivered as THC-HS via the suppository formulation. In support of the pharmacokinetic evaluations, [...]
Lire la suiteHuman Pharmacokinetics and Adverse Effects of Pulmonary and Intravenous THC-CBD Formulations Pascale Meyer, Manuela Langos, Rudolf Brenneisen Medical Cannabis and Cannabinoids, 2018, 1, 36–43 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489034 Abstract Background : Due to variable absorption and extensive firstpass metabolism, the bioavailability of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is low, and, therefore, alternative application forms are necessary. Methods : In an open-label, 2-period phase-1 study on 11 healthy volunteers, a combination of THC and CBD was compared by pulmonary (inh) and intravenous (iv) application. The liquid aerosol was produced by an in vitro validated pressurized metered-dose inhaler (pMDI) device, releasing 41–44% [...]
Lire la suite